{"id":210713,"name":"REGENXBIO","slug":"regenxbio","state":"MD","country":"United States of America","description":"Develop innovative therapies to treat patients with rare or otherwise debilitating disease","totalSpending":665000,"filings":13,"yearlySpending":[{"year":2021,"income":180000},{"year":2022,"income":240000},{"year":2023,"income":230000},{"year":2024,"income":15000}],"issues":["MMM","TAX","HCR","PHA"],"firms":["KNIGHT CAPITOL CONSULTANTS"],"lobbyists":["PATRICIA KNIGHT"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["Development of innovative therapies using gene therapy; biomedical research; Prescription drug user fee implementing legislation","Potential changes in the corporate tax rate or other provisions of interest to business (no specific bill)","Potential legislation implementing value based purchasing for pharmaceuticals (no specific bill); Possible provisions of Drug Pricing Legislation (H.R. 3, H.R. 19, S. 2543 and successor legislation) t","Inclusion of provisions affecting the reimbursement of gene therapies that may be included in any drug pricing legislation or legislation on infrastructure (no specific bills)","Possible legislation which may affect Food and Drug Administration review of biologic products (no specific bill)"],"years":[2021,2022,2023,2024]}